Limitations in Analytical Method Development for Biologics Using Classical OFAT Approaches

Traditional analytical method development often relies on one-factor-at-a-time (OFAT) experimentation, where a single parameter is varied while all others are held constant. While straightforward to execute, this approach has fundamental limitations:

• Interactions between method parameters remain hidden
• Robustness is evaluated incompletely or too late
• Methods perform well only under narrowly defined conditions
• Transfer, scale-up, and lifecycle changes introduce avoidable risk

For biologics, where charge variants, structural heterogeneity, and subtle physicochemical differences are critical, OFAT approaches frequently result in fragile methods that struggle during method transfer or post-approval changes. In practice, this leads to late-stage rework, failed transfers, and avoidable regulatory scrutiny.

What DoE Enables in Practice for Biologics

When applied correctly, DoE transforms analytical development from reactive troubleshooting into predictive control. In analytical method development for biologics, DoE enables teams to:

• Improve resolution between closely related variants
• Stabilize pI determination and reduce variability
• Enhance signal-to-noise ratio and detection confidence
• Define a safe operating range for method parameters
• Reduce risk during method transfer and lifecycle changes

This shift is particularly important for monoclonal antibodies and other biologics, where analytical uncertainty directly translates into development, manufacturing, and regulatory risk.

Practical Impact of DoE in Analytical Method Development for Biologics

When applied correctly, DoE transforms analytical development from reactive troubleshooting into predictive control. In practice, DoE enables analytical teams to:

• Improve resolution between closely related variants
• Stabilize pI determination and reduce variability
• Enhance signal-to-noise ratio and detection confidence
• Define a safe operating range for method parameters
• Reduce risk during method transfer and lifecycle changes

This shift is particularly important for biologics, where analytical uncertainty directly translates into development, manufacturing, and regulatory risk.

Case Study: DoE-Based icIEF Method Development for Monoclonal Antibodies

A concrete example of DoE in analytical method development for biologics is detailed in a Wiley Analytical Science article by Dr. Anamarija Ćurić, Founder & CEO of nuvalore.

In this study, a DoE-driven strategy was used to optimize an imaged capillary isoelectric focusing (icIEF) method for charge variant analysis of a monoclonal antibody.

Key elements of the study included:

• Systematic risk assessment using an Ishikawa (cause-and-effect) analysis to identify key variability drivers
• Screening of multiple parameters via a fractional factorial DoE
• Identification of main effects and parameter interactions
• Detection of nonlinear behavior using center points
• Definition of a Method Operable Design Region (MODR)

Rather than optimizing a single “best” condition, the study focused on understanding how method parameters interact and where the method remains reliable. The result was a robust analytical method with a scientifically justified operating space — supporting transferability, lifecycle flexibility, and regulatory confidence.

Read the full article on Wiley Analytical Science

Why the Method Operable Design Region (MODR) Matters

One of the most powerful outcomes of DoE-based analytical method development for biologics is the definition of a Method Operable Design Region (MODR) — a scientifically justified operating space within which method performance remains acceptable and parameter adjustments can be made without full revalidation.

From a regulatory perspective, an MODR supports greater flexibility during development and post-approval changes, reduces risk during method transfer, and strengthens justification in regulatory submissions. In effect, DoE transforms method changes from a regulatory liability into a controlled, science-based decision.

DoE as a Platform Strategy in Biologics Development

The full value of DoE emerges when it is applied as a platform strategy rather than as a one-off experimental tool. In analytical method development for biologics, well-designed DoE studies enable:

• Knowledge transfer across similar molecules
• Faster method development for follow-on programs
• More consistent analytical performance across portfolios

For monoclonal antibodies and other complex biologics where analytical challenges often recur, this approach builds cumulative scientific understanding rather than isolated solutions.

How nuvalore Applies DoE in Analytical Method Development for Biologics

At nuvalore, DoE is an integral component of analytical method development for biologics under GMP conditions. Our scientists apply structured, risk-based analytical method development principles aligned with AQbD and ICH expectations to:

• Analytical method development, validation, and transfer
• Charge variant analysis, including icIEF method development
• Robustness studies and lifecycle management
• AQbD-aligned analytical strategies for biologics

The objective is consistent: reduce uncertainty, increase confidence, and build robust analytical methods that remain reliable through validation, transfer, and regulatory review.

Designing Robust Analytical Methods for Biologics by Intent

Design of Experiments has fundamentally reshaped analytical method development for biologics. By moving beyond single-factor studies and trial-and-error approaches, DoE enables deeper scientific understanding, structured risk control, and enhanced regulatory flexibility.

As demonstrated in the case study, DoE is not merely a statistical tool — it is a strategic framework for risk-based analytical method development in modern pharmaceutical analytics.

Interested in applying DoE to your analytical method development for biologics? Contact nuvalore’s scientific experts to discuss how a structured, AQbD-aligned strategy can support your program from early development through validation and lifecycle management.